Open an account

Passage Bio

PASG · NASDAQ

$3.60+$0.02 (+0.56%)TodayMarket closed ·
Prev close $3.58

About PASG

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Employees
24
Headquarters
PHILADELPHIA, Pennsylvania
Listed
Feb 28, 2020
Sector
Health Care
Industry
Biotechnology
Website
passagebio.com

PASG key statistics

Market cap
11.52M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
23.27K
Volume
5.66K
Open price
$3.52
High today
$3.68
Low today
$3.45
52 Week high
$20.00
52 Week low
$3.29

Passage Bio (PASG) at a glance

Passage Bio (PASG) last traded at $3.60, with a market cap of 11.52M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.45 and $3.68. The current price is 4.2% above the day's low and 2.2% below its high.

Volume so far is 5.66K shares, below the average of 23.27K shares a day.

Over the past year Passage Bio has ranged from $3.29 to $20.00, and now sits 2% of the way up that range.

Passage Bio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$2.44 per share against an estimate of -$2.70.

The average analyst price target is $15.81, 339.2% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 6 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $15.81
Low
$8.08
Now
$3.60
High
$24.15

PASG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 16.1% on average.

  1. Q3 FY24: reported -$6.20 per share against an estimate of -$4.69
  2. Q4 FY24: reported -$4.00 per share against an estimate of -$4.16
  3. Q1 FY25: reported -$5.00 per share against an estimate of -$4.69
  4. Q2 FY25: reported -$2.96 per share against an estimate of -$4.13
  5. Q3 FY25: reported -$2.44 per share against an estimate of -$2.86
  6. Q4 FY25: reported -$3.95 per share against an estimate of -$2.62
  7. Q1 FY26: reported -$2.16 per share against an estimate of -$2.85
  8. Q2 FY26: reported -$2.44 per share against an estimate of -$2.70

PASG news

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG

  • Avi Kapoor

    Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings

  • Avi Kapoor

    US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

  • Press releaseGlobe Newswire

    Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

  • Press releaseGlobe Newswire

    Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

  • Press releaseGlobe Newswire

    Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

  • Press releaseGlobe Newswire

    Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Passage Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.